Karin Innes is a partner in our Melbourne biotechnology team.
Karin’s technical knowledge covers a range of technologies including stem cells, immunology, CAR-T/DC cell technology, antibodies, aptamers, medical devices, diagnostics, PCR technology, women’s health, gene therapy and virology. She advises clients in all stages of patent procurement, patent strategy, due diligence and freedom to operate, and is passionate about working with her clients to align their IP with their commercial strategy. She has also worked on a number of opposition cases before the Australian and New Zealand patent offices, and has assisted clients in the preparation of their prospectus for listing on the Australia stock exchange, as well as in the preparation of ASX announcements. Karin represented Ganymed Pharmaceuticals in the successful patent prosecution case before the IP Office of New Zealand; resulting in FB Rice winning “New Zealand Impact Case of the Year” at the Managing IP Asia Pacific Awards 2022. Karin has been endorsed in the IAM Prosecution recommended list each year since 2020.